Associated Papers
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.
Hamid AB et al.
Cancers, 2020
Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML).
Wu J et al.
Cancer Biology & Therapy, 2019
Oncogene mutational analysis in Chinese gastrointestinal stromal tumor patients.
Chen Q et al.
Oncotargets and Therapy, 2018
COSMIC: High-Resolution Cancer Genetics Using the Catalogue of Somatic Mutations in Cancer.
Forbes SA et al.
Current Protocols in Human Genetics, 2016
A historical overview of protein kinases and their targeted small molecule inhibitors.
Roskoski R
Pharmacological Research, 2015
Imatinib mesylate.
Waller CF
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer, 2014
Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients.
Elias MH et al.
Hematology Reports, 2012
BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?
Gruber FX et al.
Medical Oncology (northwood, London, England), 2012
Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.
Chan WW et al.
Cancer Cell, 2011
Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
Zhou T et al.
Chemical Biology & Drug Design, 2011
Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays.
Yin CC et al.
Cancer Science, 2010
Imatinib mesylate.
Waller CF
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer, 2010
Strategies for overcoming imatinib resistance in chronic myeloid leukemia.
Kujawski L et al.
Leukemia & Lymphoma, 2007
Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.
Nicolini FE et al.
Haematologica, 2007
Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia.
Kong JH et al.
Acta Haematologica, 2007
The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.
Tokarski JS et al.
Cancer Research, 2006
Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib.
Kang HY et al.
Haematologica, 2006
BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy?
Lange T et al.
Cell Cycle (georgetown, Tex.), 2005
Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography.
Deininger MW et al.
Leukemia, 2004
Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment.
Roche-Lestienne C et al.
Seminars in Hematology, 2003
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.
Azam M et al.
Cell, 2003
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
Shah NP et al.
Cancer Cell, 2002
Imatinib Mesylate.
Waller CF
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer, 0